Kristie L. Kahl

The Food and Drug Administration approved filgrastim-aafi (Nivestym), a biosimilar to filgrastim (Neupogen), for all eligible indications of the original product.

Treatment with niraparib (Zejula) demonstrated durable responses among women with relapsed or refractory ovarian cancer regardless of BRCA mutation, study shows.

Not enough discussions are occurring between oncologists and patients with advanced cancer around goals of care.

Based on the identification of 6 gene variations that make carriers susceptible to developing medulloblastoma and possibly other cancers, researchers have proposed subgroup-based counseling and screening recommendations.

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis, according to phase III study results presented at the 2018 ASCO Annual Meeting.

The FDA granted a priority review to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of previously treated patients with advanced hepatocellular carcinoma.

Troubling statistics indicate that women who have head and neck cancer have worse out comes than their male counterparts.

The American Cancer Society recently updated its guidelines to lower the age to start colorectal cancer screening to 45. Nurses will play a vital role in implementing this important change.

The FDA granted a priority review to the anti-PD-1 agent pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression.

The FDA granted a priority review to a new drug application for glasdegib, an investigational oral smoothened inhibitor, for the treatment of adult patients with previously untreated acute myeloid leukemia in combination with low-dose cytarabine, a type of chemotherapy.

The FDA granted priority review to a supplemental Biologics License Application for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for an expanded age indication,

An off-the-shelf, dual-targeted chimeric antigen receptor (CAR) T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.

The FDA approved sargramostim (Leukine) for the treatment of adult and pediatric with hematopoietic subsyndrome of acute radiation syndrome (H-ARS).

The FDA approved pegfilgrastim-jmdb (Fulphila) as the first biosimilar to pegfilgrastim (Neulasta), a drug designed to reduce the risk of febrile neutropenia in patients treated with chemotherapy in certain types of cancer, according to a press release issued by the FDA.

Oncology nurses play an important role in educating patients with chronic lymphocytic leukemia (CLL) about the adverse effects (AEs) associated with ibrutinib (Imbruvica) treatment.

A symptom assessment app used at home may empower education and self-management among patients, and help with clinician communication.

While the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) shows promise for a subgroup of patients with metastatic colorectal cancer (mCRC), 32% still experienced a treatment-related adverse effect.

Adding patient engagement strategies can help to enhance the research agenda for oncology nursing.

The National Colorectal Cancer Roundtable has created a special toolkit to help physicians successfully determine and evaluate family history to detect colorectal cancer at an earlier age.

One drug may have discovered a path to overcome a particularly difficult hurdle in brain cancer treatment.

BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.

Systematic exposure to bright morning light could help patients with cancer and survivors sleep better and experience less fatigue.

The Pivot Nurse in Oncology (PNO) role appears to make a substantial difference in care for patients being treated for advanced lung cancer, according to a study presented at the European Lung Cancer Congress (ELCC) 2018.

While the new FDA approval of 4-week dosing adds more flexibility in scheduling, it reduces the number of times patients would be monitored in person for adverse effects (AEs), so nurses need to be alert to and educated about potential AEs.

Fear of cancer recurrence is considered one of the most prominent concerns for patients following a cancer diagnosis – a concern nurses can address when creating optimal survivorship care.

A non-profit organization has dedicated its efforts to raise awareness around the conversations healthcare teams should be having with patients about clinic trial enrollment.

Radiotherapy treatments for Hodgkin lymphoma may raise the risk of certain breast cancer subtypes, a study of data on women survivors from the Surveillance, Epidemiology, and End Results (SEER) registries revealed.

It is important for nurses to help patients implement physical interventions that are feasible and acceptable for those with colorectal cancer diagnoses.

As part of a multidisciplinary team, nurses often reference guidelines to assist in treatment decisions for patients with cancer. Now, they also have guidance on how to treat individuals that comprise an underserved population of patients: those living with HIV and cancer.